Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Fuji
Chinese Patent Office
Baxter
Boehringer Ingelheim
Federal Trade Commission
UBS
Merck
QuintilesIMS

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,835,501

« Back to Dashboard

Which drugs does patent 8,835,501 protect, and when does it expire?

Patent 8,835,501 protects BELEODAQ and is included in one NDA.

This patent has thirty-six patent family members in twenty-six countries.
Summary for Patent: 8,835,501
Title:Pharmaceutical formulations of HDAC inhibitors
Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s): Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee: TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:11/913,191
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,835,501

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,835,501

PCT Information
PCT FiledMay 11, 2006PCT Application Number:PCT/GB2006/001737
PCT Publication Date:November 16, 2006PCT Publication Number: WO2006/120456

Non-Orange Book US Patents Family Members for Patent 8,835,501

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,856,211 Pharmaceutical formulations of HDAC inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,835,501

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2606598 ➤ Try a Free Trial
China 101189003 ➤ Try a Free Trial
China 102579417 ➤ Try a Free Trial
Cyprus 1112498 ➤ Try a Free Trial
Denmark 1901729 ➤ Try a Free Trial
Denmark 2494969 ➤ Try a Free Trial
Eurasian Patent Organization 200702467 ➤ Try a Free Trial
Eurasian Patent Organization 018982 ➤ Try a Free Trial
Eurasian Patent Organization 201370122 ➤ Try a Free Trial
Eurasian Patent Organization 023400 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Accenture
Cerilliant
Merck
Queensland Health
Medtronic
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot